Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PG5G
|
|||
| Former ID |
DAP000107
|
|||
| Drug Name |
Infliximab
|
|||
| Synonyms |
Remicade (TN)
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Approved | [1], [2], [3] | |
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 3 | [1], [4] | ||
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [5] | ||
| Therapeutic Class |
Immunosuppressive Agents
|
|||
| Company |
Samsung Bioepsis
|
|||
| ADReCS Drug ID | BADD_D01157 | |||
| SuperDrug ATC ID |
L04AB02
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Acidaminococcales | ||||
|
Studied Microbe: Phascolarctobacterium
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Phascolarctobacterium was decreased by Infliximab. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacillales | ||||
|
Studied Microbe: Planococcaceae
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Planococcaceae was decreased by Infliximab (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Bifidobacterium was increased by Infliximab. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Collinsella was increased by Infliximab. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Eggerthella
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Eggerthella was increased by Infliximab. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Enterobacteriaceae was decreased by Infliximab (p < 0.05). | |||
|
Studied Microbe: Klebsiella
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Klebsiella was increased by Infliximab (p < 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Turicibacter
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Turicibacter was increased by Infliximab (p < 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Anaerostipes
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Anaerostipes was decreased by Infliximab (p < 0.001). | |||
|
Studied Microbe: Coprococcus
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Coprococcus was increased by Infliximab (p < 0.001). | |||
|
Studied Microbe: Faecalibacterium prausnitzii
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Ulcerative colitis | |||
| Description | The abundance of Faecalibacterium prausnitzii was increased by Infliximab. | |||
|
Studied Microbe: Lachnospira
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Lachnospira was increased by Infliximab (p < 0.001). | |||
|
Studied Microbe: Lachnospira
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Lachnospira was increased by Infliximab. | |||
|
Studied Microbe: Roseburia
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Roseburia was increased by Infliximab (p < 0.001). | |||
|
Studied Microbe: Roseburia faecis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Roseburia faecis was increased by Infliximab. | |||
|
Studied Microbe: Ruminococcus
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Ruminococcus was increased by Infliximab (p < 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcaceae
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Enterococcaceae was decreased by Infliximab (p < 0.05). | |||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Enterococcus was decreased by Infliximab (p < 0.001). | |||
|
Studied Microbe: Streptococcaceae
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Streptococcaceae was decreased by Infliximab (p < 0.05). | |||
|
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Streptococcus was decreased by Infliximab (p < 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Veillonella
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Veillonella was increased by Infliximab (p < 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Burkholderiales
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Rheumatoid arthritis | |||
| Description | The abundance of Burkholderiales was increased by Infliximab. | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5004). | |||
| REF 2 | Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018 | |||
| REF 4 | Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008 Mar;7(1):53-66. | |||
| REF 5 | ClinicalTrials.gov (NCT00029042) Infliximab to Treat Children With Juvenile Rheumatoid Arthritis | |||
| REF 6 | Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. Clin Transl Sci. 2020 Mar;13(2):238-259. | |||
| REF 7 | Characteristics of Faecal Microbiota in Paediatric Crohn's Disease and Their Dynamic Changes During Infliximab Therapy. J Crohns Colitis. 2018 Feb 28;12(3):337-346. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.